The time lag between declaring a drug 'Not of Standard Quality' and regulatory action is a public-health hazard. Critically examine the proposed amendments to the Drugs Rules, 1945 in this context.

Under the Drugs Rules, 1945, a manufacturer whose drug is declared Not of Standard Quality (NSQ) must first get a show-cause notice, and the drug may stay in circulation meanwhile [1]. The Health Ministry's draft amendment would suspend the manufacturing licence immediately for failures on specified critical quality parameters [1]. It is a needed fix, but only a partial one.

Merits of the proposed amendment

• Closes the circulation window: a drug already known to be NSQ would no longer stay on sale, which the Ministry calls a "potential risk to public health" [1].
• Right to health over procedure: for critical failures, it puts Article 21 ahead of a prior hearing. Maneka Gandhi v. Union of India (1978) accepts a hearing after the action in urgent cases.
• Narrow, consultative design: only specified critical parameters trigger it, and the draft is open for 30-day public consultation [1].
• Global credibility: the WHO says at least 1 in 10 medicines in low- and middle-income countries are substandard or falsified [2]. Firm action protects India's "Pharmacy of the World" image.

Limitations

• The lab is the real bottleneck: a CAG audit of Haryana found that in 7,947 of 7,975 NSQ cases, drugs left warehouses before the test reports arrived [3].
• Suspension is not recall: it stops new production, not stock already in pharmacies and hospitals.
• Uneven State capacity: State Licensing Authorities suspend licences [4], so enforcement will vary with their staff and labs.
• Risk of wrong results: a parliamentary committee flagged weak government labs: few trained analysts, poor instruments and unvalidated methods [5]. MSMEs could be shut down on one faulty test, and the draft sets no deadline for re-testing [1].

Way forward

• Publish the list of critical parameters in the rule itself, so it cannot be applied arbitrarily.
• Set time limits for confirmatory testing and appeal, and allow a restart after root-cause analysis and corrective action.
• Pair every suspension with a batch recall, and release public-sector stock only after it clears testing.
• Strengthen State labs and inspectorates, and expand risk-based inspections, already carried out at 400 premises [6].
• Report suspensions to the WHO Global Surveillance and Monitoring System [2].

For critical failures, the amendment rightly moves from "hear first" to "act first". But faster action at the licensing stage alone cannot protect patients. Combined with faster testing, firm recalls and stronger State regulators, it can make quality assurance real. That would advance Article 21 and SDG 3.8's goal of safe, quality medicines for all.